Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AlloSure validated for transplant recipients
February 2016
SHARING OPTIONS:

BRISBANE, Calif.—CareDx Inc. recently completed the analytical validation for AlloSure, its proprietary next-generation sequencing test for measuring the percentage of donor-derived cell-free DNA (dd-cfDNA) in solid organ transplant recipients. The test quantifies dd-cfDNA in transplant recipients without knowledge of the donor or recipient genotype. Last year, CareDx shared preliminary data on how dd-cfDNA increases prior to immune rejection and decreases after immunosuppressive therapy in heart and kidney transplant patients. The company used the National Institute of Standards and Testing human reference genome to validate AlloSure to ensure its accuracy and reproducibility.
 
“AlloSure is an innovative approach to better understand the underlying pathology of transplantation genomics,” Dr. Peter Maag, CEO and president of CareDx, said. “It builds on our commitment and experience with AlloMap, our surveillance solution for heart transplant patients.”   

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.